Drug Trial Radar · NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
May 4, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C. People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.
Conditions
- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Pancreatic Adenocarcinoma
Interventions
ASP546CDrug
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 36 Months
- Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug ConjugateTime frame: Up to 39 Months
- Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax)Time frame: Up to 39 Months
- Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d)Time frame: Up to 39 Months
- Part 1: Number of participants with Adverse events (AEs)Time frame: Up to 39 Months
- Part 1: Number of Participants with Vital Sign Abnormalities and/or AEsTime frame: Up to 39 Months
- Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEsTime frame: Up to 39 Months
- Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status ScoresTime frame: Up to 39 Months
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
UAB Medicine - UAB Hospital
Birmingham, Alabama · Recruiting
START Los Angeles
Los Angeles, California · Recruiting
UC Irvine Health-Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California San Francisco (UCSF) Medical Center
San Francisco, California · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Winship Cancer Institute at Emory University
Atlanta, Georgia · Recruiting
Indiana University (IU) Health - Multi-D Oncology Clinic
Indianapolis, Indiana · Recruiting
Barbara Ann Karmanos Cancer Center
Detroit, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Health Partners Frauenshuh Cancer Center
Saint Louis Park, Minnesota · Recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire · Recruiting
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center Monmouth
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Memorial Sloan Kettering Commack
Commack, New York · Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York · Recruiting
START New York
Lake Success, New York · Recruiting
Memorial Sloan Kettering Cancer Center
Long Island City, New York · Recruiting
Memorial Sloan Kettering Nassau
Uniondale, New York · Recruiting
Duke Cancer Center Durham
Durham, North Carolina · Recruiting
Mercy Coletta Cancer Center
Oklahoma City, Oklahoma · Recruiting
Next Oncology - Austin
Austin, Texas · Recruiting
Next Oncology - Houston
Houston, Texas · Recruiting
Next Oncology - Dallas
Irving, Texas · Recruiting
START San Antonio (STSA)
San Antonio, Texas · Recruiting
Huntsman Cancer Institute University of Utah
Salt Lake City, Utah · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
Inova Schar Cancer Institute Clinical Trials
Fairfax, Virginia · Recruiting
Virginia Mason Medical Center
Seattle, Washington · Recruiting
UW Health Carbone Cancer Center
Madison, Wisconsin · Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.